Integral Derivatives’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Integral Derivatives’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$256K	Sell	2,917 -7,400	-72%	-$676K	0.01%	549
2017 Q4	$876K	Buy	10,317 +1,300	+14%	+$109K	0.02%	533
2017 Q3	$781K	Buy	+9,017	New	+$723K	0.01%	583
2017 Q2	–	Sell	-4,623	Closed	-$328K	–	1306
2017 Q1	$321K	Buy	+4,623	New	+$310K	0.01%	884
2016 Q4	–	Sell	-6,687	Closed	-$413K	–	1281
2016 Q3	$443K	Sell	6,687 -313	-4%	-$19.4K	0.01%	672
2016 Q2	$379K	Sell	7,000 -3,398	-33%	-$186K	0.01%	678
2016 Q1	$537K	Buy	+10,398	New	+$540K	0.02%	509
2015 Q4	–	Sell	-7,992	Closed	-$545K	–	1250
2015 Q3	$498K	Buy	+7,992	New	+$630K	0.01%	710

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Integral Derivatives's XBI Position: Q1 2018 in Review

Integral Derivatives reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 72% in Q1 2018, selling an estimated $676K and leaving 2,917 shares worth $256K. The position accounts for 0.01% of the portfolio, ranked #549.

Integral Derivatives first reported a position in XBI in Q3 2015 and has held it in 8 quarters since. The position peaked at $876K in Q4 2017. 414 funds tracked by Wall St. Rank hold XBI as of Q1 2018.

Integral Derivatives held 2,917 shares of State Street SPDR S&P Biotech ETF worth $256K as of Q1 2018.
Integral Derivatives sold 7,400 State Street SPDR S&P Biotech ETF shares in Q1 2018, an estimated $676K.
State Street SPDR S&P Biotech ETF made up 0.01% of Integral Derivatives's portfolio in Q1 2018, its #549 holding.
Integral Derivatives first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and has held it in 8 quarters since.
Integral Derivatives's State Street SPDR S&P Biotech ETF position peaked at $876K in Q4 2017.
414 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.